

Fujita International Symposium on Cancer Science 2024

Day 1 (November 15 th , Friday)	
9:30 to 9:40	Opening Remarks Yukio Yuzawa (President, Fujita Health University)
9:40 to 9:45	Overview of ONIC and Fujita International Symposium Issay Kitabayashi (Oncology Innovation Center, Fujita Health University)
9:45 to 11:05	Symposium 1: Stem Cell Malignancy Chair: Ulrich G. Steidl, Atsushi Hirao Self-Renew Activity of Aging Hematopoietic Stem Cells (40 min) Toshio Suda Nuclear phase separation drives NPM1-Mutant Acute Myeloid Leukemia (40 min) Margaret A. Goodell
11:05 to 11:25	Break (20 min)
11:25 to 12:40	Understanding and Targeting Transcription Dynamics in Hematopoiesis and Leukemia (40 min) Ulrich G. Steidl Critical roles of metabolic and immune responses in hematopoietic stem cell homeostasis (35 min) Atsushi Hirao
12:40 to 13:40	Luncheon Seminar: Enhancing Precision in Hemato-Oncology: The Role of Rapid Molecular Profiling and NGS in AML Management Thermo Fisher Scientific
13:40 to 15:30	Symposium 2: Myeloid & Lymphoid Malignancy Chair: Patricia Ernst, Atsushi Iwama Molecular Mechanisms and Novel Targeted Therapies for Acute Myeloid Leukemia (35 min) Issay Kitabayashi Targeting the MLL complex in Leukemia (40 min) Scott Armstrong Epigenetic regulation of myeloid leukemia and therapeutic targeting of epigenetic regulators (35 min) Atsushi Iwama
15:30 to 15:50	Break (20 min)

15:50 to 17:40	<p>Modelling pediatric KMT2A-r B-ALL; insights into lineage plasticity and implications for CD19-targeted therapies (40 min) Patricia Ernst</p> <p>Understanding and Targeting Disrupted Redox System in Normal and Malignant Hematopoiesis (35 min) Daichi Inoue</p> <p>Role of the MOZ/MORF histone acetyltransferase complex in cancer (35 min) Akihiko Yokoyama</p>
17:40 to 18:00	Group photo shoot
18:15 to 20:15	Evening Reception

Day 2 (November 16th, Saturday)

9:30 to 11:00	<p>Symposium 3: Lymphoid Malignancy</p> <p>Chair: Akihiro Tomita, Makoto Yamagishi</p> <p>Usefulness of genetic analysis using liquid biopsy technique in clinical setting of malignant lymphoma (30 min)</p> <p style="text-align: right;">Akihiro Tomita</p> <p>BETP-driven Livin confers resistance to Fas-mediated immune cytotoxicity in refractory B-cell lymphomas (30 min)</p> <p style="text-align: right;">Eiji Sugihara</p> <p>Epstein-Barr virus and lymphomatogenesis (30 min)</p> <p style="text-align: right;">Takayuki Murata</p>
11:00 to 11:20	<p>Break (20 min)</p>
11:20 to 12:20	<p>Transcriptional program driven by oncogenic master transcription factors in T-cell acute lymphoblastic leukemia (30 min)</p> <p style="text-align: right;">Takaomi Sanda</p> <p>Epigenetic characteristics and therapeutic strategies in malignant lymphomas (30 min)</p> <p style="text-align: right;">Makoto Yamagishi</p>
12:20 to 13:20	<p>Lunch (60 min)</p>
13:20 to 15:00	<p>Symposium 4: Novel Therapy</p> <p>Chair: Geoffrey R. Hill, Yoshihiro Inamoto</p> <p>The modulation of antigen presentation and T cell differentiation to control immune toxicity and tumor immunity (40 min)</p> <p style="text-align: right;">Geoffrey R. Hill</p> <p>Therapeutic strategy for acute myeloid leukemia with FLT3 mutations (30 min)</p> <p style="text-align: right;">Hitoshi Kiyoi</p> <p>Novel drugs for graft-versus-host disease after hematopoietic cell transplantation (30 min)</p> <p style="text-align: right;">Yoshihiro Inamoto</p>
15:00 to 15:10	<p>Closing Remarks</p> <p>Hideyuki Saya (Oncology Innovation Center, Fujita Health University)</p>